A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

NCT02732184 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Co-ArgI-PEG modified human arginase I

Sponsor

Aeglea Biotherapeutics